CDK2/4/6 inhibitor RGT-419B

{
  "id": "MLC-T-ONC-012450",
  "term": "CDK2/4/6 inhibitor RGT-419B",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable third-generation inhibitor of cyclin-dependent kinase (CDK) types 2 (CDK2), 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon oral administration, CDK2/4/6 inhibitor RGT-419B selectively targets and inhibits CDK2, CDK4 and CDK6, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase and prevents CDK-mediated G1-S-phase transition. This leads to cell cycle arrest, the induction of apoptosis, and the inhibition of tumor cell proliferation. CDKs are serine/threonine kinases that are important regulators of cell cycle progression and cellular proliferation and are upregulated in many tumor cell types. In addition, RGT-419B may inhibit other kinases.",
  "synonyms": [
    "cyclin-dependent kinase 2/4/6 inhibitor RGT-419B"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/cdk2-4-6-inhibitor-rgt-419b/"
}